O'Brien NA - Search Results

1

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.

Canonici A, Qadir Z, Conlon NT, Collins DM, O'Brien NA, Walsh N, Eustace AJ, O'Donovan N, Crown J. Canonici A, et al. Invest New Drugs. 2018 Aug;36(4):581-589. doi: 10.1007/s10637-017-0556-7. Epub 2018 Feb 2. Invest New Drugs. 2018. PMID: 29396630

2

Mammaglobin a: a promising marker for breast cancer.

O'Brien N, Maguire TM, O'Donovan N, Lynch N, Hill AD, McDermott E, O'Higgins N, Duffy MJ. O'Brien N, et al. Clin Chem. 2002 Aug;48(8):1362-4. Clin Chem. 2002. PMID: 12142396 No abstract available.

3

Mammaglobin a in breast cancer: existence of multiple molecular forms.

O'Brien NA, O'Donovan N, Ryan B, Hill AD, McDermott E, O'Higgins N, Duffy MJ. O'Brien NA, et al. Int J Cancer. 2005 Apr 20;114(4):623-7. doi: 10.1002/ijc.20780. Int J Cancer. 2005. PMID: 15609337

4

Use of a panel of novel genes for differentiating breast cancer from non-breast tissues.

O'Brien N, O'Donovan N, Foley D, Hill AD, McDermott E, O'Higgins N, Duffy MJ. O'Brien N, et al. Tumour Biol. 2007;28(6):312-7. doi: 10.1159/000115527. Epub 2008 Feb 5. Tumour Biol. 2007. PMID: 18253069

5

HER-2 signaling and inhibition in breast cancer.

Browne BC, O'Brien N, Duffy MJ, Crown J, O'Donovan N. Browne BC, et al. Curr Cancer Drug Targets. 2009 May;9(3):419-38. doi: 10.2174/156800909788166484. Curr Cancer Drug Targets. 2009. PMID: 19442060 Review.

6

Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.

O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ. O'Brien NA, et al. Mol Cancer Ther. 2010 Jun;9(6):1489-502. doi: 10.1158/1535-7163.MCT-09-1171. Epub 2010 May 25. Mol Cancer Ther. 2010. PMID: 20501798

7

Current approaches and future directions in the treatment of HER2-positive breast cancer.

Hurvitz SA, Hu Y, O'Brien N, Finn RS. Hurvitz SA, et al. Cancer Treat Rev. 2013 May;39(3):219-29. doi: 10.1016/j.ctrv.2012.04.008. Epub 2012 May 31. Cancer Treat Rev. 2013. PMID: 22658319 Free PMC article. Review.

8

Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.

Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS. Kalous O, et al. Mol Cancer Ther. 2012 Sep;11(9):1978-87. doi: 10.1158/1535-7163.MCT-11-0730. Epub 2012 Jul 3. Mol Cancer Ther. 2012. PMID: 22761403

9

Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.

Browne BC, Eustace AJ, Kennedy S, O'Brien NA, Pedersen K, McDermott MS, Larkin A, Ballot J, Mahgoub T, Sclafani F, Madden S, Kennedy J, Duffy MJ, Crown J, O'Donovan N. Browne BC, et al. Breast Cancer Res Treat. 2012 Dec;136(3):717-27. doi: 10.1007/s10549-012-2260-9. Epub 2012 Nov 2. Breast Cancer Res Treat. 2012. PMID: 23117852

10

Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.

Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D, Ayala R, O'Brien NA, Quadt C, Akimov M, Slamon DJ, Finn RS. Wainberg ZA, et al. Mol Cancer Ther. 2013 Apr;12(4):509-19. doi: 10.1158/1535-7163.MCT-12-0507. Epub 2013 Feb 8. Mol Cancer Ther. 2013. PMID: 23395886

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters